Retatrutide cuts weight about 21 percent in diabetes trial at 80 weeks
Eli Lilly's TRIUMPH-2 and TRIUMPH-3 trials tested 4, 9 and 12 mg doses against placebo; results are not yet peer-reviewed.
MH
By Maren Holt · Senior Reporter, GLP-1
Jul 23 03:00 ETSource: Everyday Health
The wire
- 01TRIUMPH-2 randomized adults with type 2 diabetes to placebo or retatrutide 4, 9 or 12 mg for 80 weeks, with nearly 21 percent average weight loss at the top dose and a 1.6 percent average A1C drop.
- 02TRIUMPH-3 enrolled roughly 2,000 adults with BMI of 40 or higher and cardiovascular disease, testing 9 and 12 mg doses, a population clinicians rarely see represented in obesity drug trials.
- 03Retatrutide is a triple agonist at GLP-1, GIP and glucagon receptors and is not FDA-approved; the trials were funded by Eli Lilly and the data have not been published in a peer-reviewed journal.
From the source
Read at everydayhealth.comRetatrutide Helped Adults With Diabetes or Heart Disease Lose Up to 20 Percent of Their Weight, Study Finds
The new clinical trials were funded by Eli Lilly, and the results have not yet been published in a peer-reviewed journal.